246 related articles for article (PubMed ID: 31943574)
1. Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach.
Le Large TYS; Meijer LL; Paleckyte R; Boyd LNC; Kok B; Wurdinger T; Schelfhorst T; Piersma SR; Pham TV; van Grieken NCT; Zonderhuis BM; Daams F; van Laarhoven HWM; Bijlsma MF; Jimenez CR; Giovannetti E; Kazemier G
Oncologist; 2020 Apr; 25(4):e634-e643. PubMed ID: 31943574
[TBL] [Abstract][Full Text] [Related]
2. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.
Kim J; Bamlet WR; Oberg AL; Chaffee KG; Donahue G; Cao XJ; Chari S; Garcia BA; Petersen GM; Zaret KS
Sci Transl Med; 2017 Jul; 9(398):. PubMed ID: 28701476
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma.
Byrling J; Hilmersson KS; Ansari D; Andersson R; Andersson B
Clin Transl Oncol; 2022 Feb; 24(2):297-304. PubMed ID: 34319497
[TBL] [Abstract][Full Text] [Related]
4. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
5. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.
Singh S; Tang SJ; Sreenarasimhaiah J; Lara LF; Siddiqui A
Dig Dis Sci; 2011 Aug; 56(8):2491-6. PubMed ID: 21516323
[TBL] [Abstract][Full Text] [Related]
6. The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel Approach.
Boyd LNC; Ali M; Kam L; Puik JR; Rodrigues SMF; Zwart ES; Daams F; Zonderhuis BM; Meijer LL; Le Large TYS; Giovannetti E; van Laarhoven HWM; Kazemier G
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053506
[TBL] [Abstract][Full Text] [Related]
7. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.
Udgata S; Takenaka N; Bamlet WR; Oberg AL; Yee SS; Carpenter EL; Herman D; Kim J; Petersen GM; Zaret KS
Cancer Prev Res (Phila); 2021 Feb; 14(2):223-232. PubMed ID: 33067248
[TBL] [Abstract][Full Text] [Related]
8. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
[TBL] [Abstract][Full Text] [Related]
9. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
10. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
Capello M; Bantis LE; Scelo G; Zhao Y; Li P; Dhillon DS; Patel NJ; Kundnani DL; Wang H; Abbruzzese JL; Maitra A; Tempero MA; Brand R; Firpo MA; Mulvihill SJ; Katz MH; Brennan P; Feng Z; Taguchi A; Hanash SM
J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376157
[TBL] [Abstract][Full Text] [Related]
11. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.
Leelawat K; Sakchinabut S; Narong S; Wannaprasert J
BMC Gastroenterol; 2009 Apr; 9():30. PubMed ID: 19405942
[TBL] [Abstract][Full Text] [Related]
12. Mass spectrometry-based analysis of formalin-fixed, paraffin-embedded distal cholangiocarcinoma identifies stromal thrombospondin-2 as a potential prognostic marker.
Byrling J; Kristl T; Hu D; Pla I; Sanchez A; Sasor A; Andersson R; Marko-Varga G; Andersson B
J Transl Med; 2020 Sep; 18(1):343. PubMed ID: 32887625
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
Kruger D; Yako YY; Devar J; Lahoud N; Smith M
PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
[TBL] [Abstract][Full Text] [Related]
14. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
[TBL] [Abstract][Full Text] [Related]
15. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer.
Abe T; Koi C; Kohi S; Song KB; Tamura K; Macgregor-Das A; Kitaoka N; Chuidian M; Ford M; Dbouk M; Borges M; He J; Burkhart R; Wolfgang CL; Klein AP; Eshleman JR; Hruban RH; Canto MI; Goggins M
Clin Gastroenterol Hepatol; 2020 May; 18(5):1161-1169.e5. PubMed ID: 31676359
[TBL] [Abstract][Full Text] [Related]
16. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
[TBL] [Abstract][Full Text] [Related]
17. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer.
Berger AW; Schwerdel D; Reinacher-Schick A; Uhl W; Algül H; Friess H; Janssen KP; König A; Ghadimi M; Gallmeier E; Bartsch DK; Geissler M; Staib L; Tannapfel A; Kleger A; Beutel A; Schulte LA; Kornmann M; Ettrich TJ; Seufferlein T
Theranostics; 2019; 9(5):1280-1287. PubMed ID: 30867830
[TBL] [Abstract][Full Text] [Related]
18. Circulating Thrombospondin-2 enhances prediction of malignant intraductal papillary mucinous neoplasm.
Simpson RE; Yip-Schneider MT; Wu H; Fan H; Liu Z; Korc M; Zhang J; Schmidt CM
Am J Surg; 2019 Mar; 217(3):425-428. PubMed ID: 30293901
[TBL] [Abstract][Full Text] [Related]
19. CD63-positive extracellular vesicles are potential diagnostic biomarkers of pancreatic ductal adenocarcinoma.
Odaka H; Hiemori K; Shimoda A; Akiyoshi K; Tateno H
BMC Gastroenterol; 2022 Mar; 22(1):153. PubMed ID: 35350978
[TBL] [Abstract][Full Text] [Related]
20. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris-Stiff G; Teli M; Jardine N; Puntis MC
Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
